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include these effects and this appears not to inﬂuence results in
general. More empirical work is needed, using generic instru-
ments, larger and more relevant samples, and perhaps using the
interview method of administration.
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OBJECTIVES: Expensive drugs for rare disorders (EDRDs;
“orphan drugs”) do not usually meet widely applied cost-
effectiveness benchmarks (“lambdas”). Adopting the standard
decision rules of the logic cost-effectiveness cannot be reconciled
with granting reimbursement status for many EDRDs and would
inevitably deprive patients with very rare disorders from any
chance to get access to effective treatment, given the high ﬁxed /
low variable cost structure of the pharmaceutical industry. On
the other hand, public policies have been established to provide
incentives to support development of orphan drugs. This (and
some further observations) suggests a serious mismatch between
the logic of cost-effectiveness and societal preferences. Decision-
makers have responded; for instance, the National Institute for
Health and Clinical Excellence (NICE) attempts to deﬁne a
special subcategory of “ultra-orphans”—while maintaining that
budgetary impact analysis is not part of its appraisal decisions
(but limited to implementation support). This policy, however,
does not appear to adequately address the underlying problem.
METHODS: First, “ultra-orphans” are not a distinct, well-
deﬁned category—they rather represent one extreme of a
continuous spectrum, and “orphan drugs” and some cancer
treatments pose the same fundamental problem. Second, size of a
patient population eligible for treatment is directly linked to
budgetary impact (and hence the opportunity for manufacturers
to recoup ﬁxed costs), whereas the logic of cost-effectiveness is
impaired by not taking into account the size of the numerator
and the denominator of the incremental cost-effectiveness ratio
(ICER), which has been described as “the silence of the lambda.”
Policy makers might address these issues by explicitly taking
budgetary impact into account when deciding on maximum
reimbursement prices or by price-volume agreements. RESULTS:
Both approaches, albeit perhaps pragmatic, cannot satisfy from a
theoretical economic perspective. CONCLUSIONS: Rigorous
normative analysis and empirical research are required to further
explore the mapping of individual health-related utilities into
societal preferences (willingness-to-pay).
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OBJECTIVES: To determine if and to what extent records
obtained from PBM pharmacy claims differ from source docu-
ments obtained directly from pharmacy providers. Also this
study sought to explore possible associations between patient,
pharmacy beneﬁt, and pharmacy provider characteristics and the
likelihood a patient would have missing prescription claims.
METHODS: This study used a cross sectional survey of 1,484
patients residing in a single state with a common pharmacy
beneﬁt. Patient proﬁles describing all prescriptions ﬁlled in a
pharmacy between January 1, 2002 through June 30, 2002 of
these patients were requested directly from their pharmacy pro-
viders. Logistic regression was used to explore the factors asso-
ciated with a person receiving a prescription that did not appear
on the PBM claims. RESULTS: Of the 1484 eligible recipients
sampled, proﬁles were obtained for 323 (22%) persons and there
were analyzable proﬁles for 315 (21%) persons. Of those 2,977
prescriptions ﬁlled for the 315 persons, 207 (7.0%) were missing
from the claims ﬁles indicating that 93% were captured. Pre-
scription drugs such as iron products, digoxins, diuretics, sulfo-
nylureas, and antigout were more likely to be missing from the
PBM claims. Only prescription volume consistently inﬂuenced
the likelihood a patient would have a missing prescription from
the PBM claims (OR = 1.08; 95% CI: 1.05–1.12). CONCLU-
SIONS: Claims obtained from pharmacy beneﬁt companies
capture approximately 93% of prescription records when veri-
ﬁed with records obtained from pharmacy providers. The rate of
missing records from PBM claims does not appear to be mean-
ingfully inﬂuenced by most ﬁnance based pharmacy beneﬁt
design features, however, certain drugs available over the counter
and less expensive drugs may have less complete claims records
compared to other classes of drugs. Higher prescription utilizers
are more likely to have prescription records ﬁlled that are not
captured by PBMs.
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OBJECTIVE: The core of a cost effectiveness model should be
guided by the underlying disease process, natural history and
how particular interventions impact on disease. The development
of conceptual models within PRO research is based on the same
rationale. The objective of this study was to explore the overlap
between cost effectiveness modelling and conceptual models for
PROs, using AD as an example. METHODS: A conceptual
model of AD was reviewed alongside a cost effectiveness model
by a team of PRO researchers and health economists. Areas of
commonality and divergence were documented and discussed.
RESULTS: Points of overlap were identiﬁed which included the
impact of AD on day to day functioning of the patient and
associated caregiver burden. This will inﬂuence the ability of the
caregiver to work and impact on other resource utilisation. This
may, also have an impact on the time to institutionalisation,
which is a major ﬁnancial burden in AD. One major area of
divergence is the emphasis in economic models on the use of
generic quality of life data; whereas conceptual models are
commonly developed to measure disease speciﬁc PRO burden.
CONCLUSIONS: The commonalities between PRO conceptual
models and health economic models indicates the potential for
developing PRO and HE models simultaneously. This is likely to
increase the validity of each of the models as well as having a
positive impact on related research e.g. through the development
of health state utilities. As a next step we are prospectively
developing a conceptual model of disease which is speciﬁcally
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